
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion is currently a clinical-stage biotech company with a promising AI platform, AI-Immunology, that is being leveraged to develop novel vaccines for cancer and infectious diseases. With a strong clinical pipeline and potential future partnerships, Evaxion is well-equipped to bring innovative treatments to patients in the market and generate significant revenue. However, there are inherent risks in the biotech industry, including challenges in technology, clinical trials, regulatory approvals, and competition, which could impact the company's success and financial performance. Investors should also closely monitor the company's updates on its EVX-01 program, which has shown promising results in advanced melanoma and could be a key driver of future partnerships and revenue growth.
Bears say
Evaxion is a clinical-stage TechBio company that aims to develop novel vaccines for cancer and infectious diseases using its AI-Immunology platform. However, their lack of commitment to further development of the GBM personalized cancer vaccine and the uncertainty surrounding their pivot into autoimmune disease therapies raise concerns for potential investors. As a financial analyst, it is important to carefully consider the company's future potential partnerships and licensing strategies before making any investment recommendations.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares